Figure 1.
Changes in lung damage before ((A) Diffuse ground glass opacities with peripheral nodular consolidation) and after administration ((B) Less peripheral ground glass opacities) of canakinumab.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.